TWO SIGMA ADVISERS, LP - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 142 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2019. The put-call ratio across all filers is 2.57 and the average weighting 0.4%.

Quarter-by-quarter ownership
TWO SIGMA ADVISERS, LP ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q4 2021$600,000
+212.5%
11,467
-8.0%
0.00%
+100.0%
Q1 2020$192,000
-75.6%
12,467
-45.7%
0.00%
-50.0%
Q4 2019$788,000
-24.0%
22,967
-83.4%
0.00%
-33.3%
Q3 2019$1,037,000
-51.6%
138,767
-15.9%
0.00%
-40.0%
Q2 2019$2,141,000
+39.7%
164,967
+31.1%
0.01%
+25.0%
Q1 2019$1,533,000
+376.1%
125,867
+345.3%
0.00%
+300.0%
Q4 2018$322,00028,2670.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q4 2019
NameSharesValueWeighting ↓
Sarissa Capital Management LP 675,000$26,203,0007.44%
EcoR1 Capital, LLC 244,950$9,509,0003.75%
Redmile Group, LLC 971,565$37,716,0003.60%
Ghost Tree Capital, LLC 120,000$4,658,0001.34%
SENZAR ASSET MANAGEMENT, LLC 144,624$5,614,304,0001.22%
GREAT POINT PARTNERS LLC 100,000$3,882,0001.11%
BB BIOTECH AG 700,000$27,174,0001.07%
Rhenman & Partners Asset Management AB 115,000$4,464,0000.79%
Lisanti Capital Growth, LLC 12,260$476,0000.72%
Rock Springs Capital Management LP 190,000$7,376,0000.55%
View complete list of INTRA CELLULAR THERAPIES INC shareholders